MedTrace Logo

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

NCT04674566 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-05-25

No results posted yet for this study

Summary

Primary objectives Part 1:

\- To evaluate the safety and tolerability of COR-101 compared to placebo

Secondary objectives Part 1:

* To evaluate the preliminary efficacy of COR-101 compared to placebo in hospitalized patients with moderate to severe COVID-19
* To assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of COR-101

Conditions

  • Covid19

Interventions

DRUG

COR-101

Administered intravenously (IV) single dose

DRUG

Placebo

Administered intravenously (IV) single dose

Sponsors & Collaborators

  • Corat Therapeutics Gmbh

    lead INDUSTRY

Principal Investigators

  • Helmut Salih · University Hospital Tübingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2022-10-30
Completion
2022-10-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04674566 on ClinicalTrials.gov